Targeting Anhedonia in Cocaine Use Disorder

Status Recruiting

Clinical Trial Summary

The purpose of this study is to examine anhedonia as a potential moderator of treatment outcomes for Cocaine Use Disorder (CUD). Specifically, this study will investigate how anhedonia affects outcomes in contingency management (CM) treatment for CUD and whether anhedonia mediates the effects of adjunctive treatment with a dopaminergic (DAergic) drug, d-amphetamine, on outcomes in CM for CUD, as well as investigate the contribution of anhedonia to overall CUD severity.

Clinical Trial Description

Recent research suggests that anhedonia is a key neurobehavioral dysfunction in Cocaine Use Disorder (CUD) that contributes to treatment outcomes. Anhedonia, defined here as lack of interest or pleasure in non-drug rewards, is frequently found in CUD and is related to neural deficits, such as low striatal dopamine and deficient activation to non-drug rewards in mesocortical circuits. Interestingly, not all individuals in CUD have these deficits. Preliminary data suggests that the presence of self-reported anhedonia predicts worse outcome in contingency management (CM) treatment of CUD. Moreover, low baseline dopamine predicts failure to attain abstinence in CM while medications that enhance DA increase CM success rates and responsiveness to rewards. This study specifically aims to test the contribution of anhedonia to overall CUD severity, the relationship of anhedonia to outcomes in CM treatment, and the mediating role of anhedonia in medication enhancement of CM in CUD. To accomplish these aims, individuals with CUD will be enrolled and will undergo 4 weeks of intensive CM treatment, either with or without treatment with the dopaminergic drug, d-amphetamine. A medication only group will be included to solely measure the effects of d-amphetamine. Anhedonia will be assessed using multi-modal subjective, psychophysiological and behavioral measures of reward functioning at baseline, and each week of treatment. Functional magnetic resonance imaging (fMRI) measures of reward functioning will also be taken at baseline and week 4 in a subset of participants (n = 24) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02773212
Study type	Interventional
Source	University of Illinois at Chicago
Contact	Laboratory Manager
Phone	312-639-1761
Email	addictionlab@uic.edu
Status	Recruiting
Phase	Phase 2
Start date	February 1, 2017
Completion date	April 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01526538` - Improving Learning-based Treatment of Cocaine Dependence With Medication	Phase 2
Completed	`NCT00877435` - Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial	N/A
Completed	`NCT00430690` - Acoustic Startle Reduction In Cocaine Dependence
Completed	`NCT00217997` - Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals	N/A
Active, not recruiting	`NCT00094315` - Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1	Phase 1
Terminated	`NCT00142883` - The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3	N/A
Completed	`NCT00218348` - Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo	Phase 2
Completed	`NCT00158132` - Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2	Phase 2
Completed	`NCT00142844` - Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1	Phase 2
Completed	`NCT00015054` - Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3	Phase 2
Completed	`NCT00000294` - Effects of Carvedilol on Cocaine Use in Humans - 11	Phase 2
Completed	`NCT00000308` - Dextroamphetamine-Cocaine Behavioral Intervention - 5	Phase 2
Completed	`NCT00000188` - Selegiline in Treatment of Cocaine Dependence - 2	Phase 2
Completed	`NCT00000306` - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3	Phase 2
Completed	`NCT00000281` - Pharmacotherapy for Schizophrenic Drug Users - 6	Phase 2
Completed	`NCT00000314` - M-CPP and Fenfluramine in Cocaine Addicts - 3	Phase 2
Completed	`NCT00000277` - Mazindol for Cocaine Abuse - 2	Phase 2
Completed	`NCT00000282` - Pemoline for Cocaine Abuse - 7	Phase 2
Completed	`NCT00000280` - Glutaminergic Agents for Cocaine Abuse - 5	Phase 1
Completed	`NCT00000278` - Disulfiram for Cocaine-Alcohol Abuse - 3	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.